AIPAAIAEC: Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
Study Details
Study Description
Brief Summary
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group
|
Drug: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
This is an observational study
|
Outcome Measures
Primary Outcome Measures
- PFS [From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months]
Progression Free Survival
Secondary Outcome Measures
- OS [From date of admission until the date of death from any cause, assessed up to 24 months]
Overall Survival
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Esophageal cancer confirmed by histopathology or cytology
-
Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy
-
Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers
-
Patients who sign informed consent and voluntarily join the study
Exclusion Criteria:
-
Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study
-
Patients who are undergoing treatment regimen of blind trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | China | 450000 |
Sponsors and Collaborators
- The First Affiliated Hospital of Zhengzhou University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022-KY-0179-002